Advanced

Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?

Johansson, Anna-Karin; Juhlin, Tord LU ; Engdahl, Johan; Lind, Stefan; Hagwall, Kristina; Rorsman, Cecilia; Fodor, Emöke; Alenholt, Anna; Paul Nordin, Astrid and Rosenqvist, Mårten, et al. (2015) In Europace 17(10). p.1514-1517
Abstract
The use of direct oral anticoagulants (DOACs) in patients undergoing elective direct current (DC) cardioversion of non-acute atrial fibrillation (AF) can potentially shorten the time from initiation of anticoagulation treatment to cardioversion, compared with warfarin. The safety of this strategy needs to be investigated. Data from subgroup analysis from clinical trials with DOAC do not clarify whether 4-week treatment with DOAC is sufficient to prevent thromboembolism (TE) after cardioversion. The aim of this retrospective study was to assess the incidence of TE in anticoagulant naive patients converted after one month's pre-treatment with dabigatran.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Europace
volume
17
issue
10
pages
1514 - 1517
publisher
Oxford University Press
external identifiers
  • pmid:26017466
  • wos:000366488600004
  • scopus:84948446428
ISSN
1532-2092
DOI
10.1093/europace/euv123
language
English
LU publication?
yes
id
ad7a7b82-daf4-45f9-88e8-8431f559cf3d (old id 5442029)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26017466?dopt=Abstract
date added to LUP
2015-06-05 20:52:21
date last changed
2017-07-30 03:22:27
@article{ad7a7b82-daf4-45f9-88e8-8431f559cf3d,
  abstract     = {The use of direct oral anticoagulants (DOACs) in patients undergoing elective direct current (DC) cardioversion of non-acute atrial fibrillation (AF) can potentially shorten the time from initiation of anticoagulation treatment to cardioversion, compared with warfarin. The safety of this strategy needs to be investigated. Data from subgroup analysis from clinical trials with DOAC do not clarify whether 4-week treatment with DOAC is sufficient to prevent thromboembolism (TE) after cardioversion. The aim of this retrospective study was to assess the incidence of TE in anticoagulant naive patients converted after one month's pre-treatment with dabigatran.},
  author       = {Johansson, Anna-Karin and Juhlin, Tord and Engdahl, Johan and Lind, Stefan and Hagwall, Kristina and Rorsman, Cecilia and Fodor, Emöke and Alenholt, Anna and Paul Nordin, Astrid and Rosenqvist, Mårten and Frick, Mats},
  issn         = {1532-2092},
  language     = {eng},
  number       = {10},
  pages        = {1514--1517},
  publisher    = {Oxford University Press},
  series       = {Europace},
  title        = {Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?},
  url          = {http://dx.doi.org/10.1093/europace/euv123},
  volume       = {17},
  year         = {2015},
}